key: cord-0690748-s2mfthwz authors: Yu, Flora; Lau, Terence Lok-Ting; Fok, Manson; Lau, Johnson Yiu-Nam; Zhang, Kang title: COVID-19 Delta Variants – Current Status and Implications as of August 2021 date: 2021-09-20 journal: Precis Clin Med DOI: 10.1093/pcmedi/pbab024 sha: 6438b7756eea9aed9b7788c000d65353d9ba633a doc_id: 690748 cord_uid: s2mfthwz The SARS-CoV-2 Delta variant has evolved as the dominant strain of the current pandemic. Studies have shown that this variant has increased infectivity/viral load, and reduced neutralization by the host antibodies from convalescent patients/vaccinees. Clinically, Delta variant infection have been observed/documented in convalescent patients/vaccinees, although with less incidence of severe diseases, but can serve as reservoir to spread the infection to the unvaccinated. The current understanding (as of August 18, 2021) on the virologic aspect (including the amino acid substitutions), clinical implications, and the public health implications will be discussed in this review, and recommendations to health authorities will be provided. Since its emergence in December 2019, COVID-19 has evolved into a pandemic. 1 As of Hence, the rapid development of variants with increased infectivity and/or escape from the host immune response is to be expected, especially with a huge pool of infected subjects globally. Note that the genetic variations may or may not lead to amino acid substitutions/variations (known as synonymous and non-synonymous substitutions). 7, 8 Even with estimated genetic variation/mutation rate of one nucleotide substitution for every 10 replications, a single infected person, presumed to carry >10 billion copies of the virus, can produce billions of variations per day. 9 When multiplied by the number of infected subjects globally, an enormous number of variants will be created. As the genetic scrambling is relatively random, most variants will have no impact. However, if the variant has increased infectivity/replication rate/genome stability, or/and can escape the host immune response, these variants can evolve as the dominant viral strain quickly. The US government SARS-CoV-2 Interagency Group developed a Variant Classification that defines three types of variants: variant of interest (VOI), variants of concern (VOC), and variant of high consequences (VOHC). 10 As of August 18, 2021, four VOCs have been reported (Table 1) . 10 The Alpha variant initially emerged in UK has since spread to >185 countries. 10, 11 Studies have shown its increased transmission ability (50% increase), secondary infection attack rate, along with increased severity based on hospitalization rates. However, this variant has minimal impact on neutralization by convalescent and post-vaccination sera. 10, 11 The Beta strain was first described in South Africa, displaying both increased transmission and host antibody neutralization escape. 10 The origin of the Gamma variant was traced to Japan/Brazil and has showed increased immune escape to neutralization antibodies. 10 COVID-19 gets its spike protein features from the coronavirus family. 17 The spike proteins are flexible and hinge at three different points, thereby allowing easier access to the receptors on human cells. 18 The receptor-binding domain (RBD) of the spike protein is the key binding element to the human angiotensin-converting enzyme 2 (hACE2) receptor. 18 Two glycans play a key role in the positioning of the RBD and binding affinity to the hACE2 receptors, and there is evidence that the unique presence of the furin cleavage site found in SARS-CoV-2 is associated with its high infectivity in lungs. 18 There are a numbers of amino acid substitutions observed with the Delta variant 15 , and the amino acid substitutions observed on the spike protein is summarized in Table 1 . Some of the notable mutations found in the Delta variant such as D614G, L452R, E484Q, P681R, and T478K, can also be linked to other variants. Since the first description of the D614G mutation in China, this amino acid substitution has remained in all subsequent VOCs, with the main attribute in its enhanced binding to hACE2 receptors. 19 A key feature is L452R, which was discovered to enhance infectivity and decrease the neutralization ability of immune sera. 20 Further studies also reported that L452R also enhances membrane fusion, viral replication, and evades the HLA-A24 cell immunity. 21 When L452R is combined with E484Q, only a slight decrease in neutralization activity of immune sera was observed in vitro. 22 The E484Q mutation has been observed to share similar immune neutralization escape properties with the E484K mutation in the Beta and Gamma variants. There were reports of reinfection being linked to the E484K mutation . 23 As E484K and E484Q are close to each other, there is the concern of reinfection potential of Delta First identified in India, the Delta variant has evolved as the major viral strain in the current pandemic. Studies have shown that clinically, in addition to increased transmissibility, the variant has a shortened incubation time, enhanced replication abilities, and more infectious compared to non-VOCs. 27 A recent study reported that viral load is 1260 times higher in Delta variant patients than the original COVID-19 strain. 27 In India, the major Delta variant-driven wave of infection started in March 2021 and started to recede by early July. 28 In UK where vaccination rate was high (76% adults), Delta variant-driven surge started in July and, and began to recede by August. 28, 29 Overall, there was a 10% global increase in the number of infections and a 3% increase in deaths reported on the week of July 13 that were believed to relate mainly to the Delta variant surge (compared to previous nine weeks with a steady decline in COVID-19 incidents). 30 In the US (with 50% of the population fully vaccinated), which had 8-14% ( The observation that Delta variant can infect vaccinees (therefore, can spread the infection) led CDC to change their recommendation that even fully vaccinated people should wear masks in indoor public places and in areas where transmission is high. 37 The upcoming public health challenges will be when children are back at school soon, and when people move indoors during the coming fall and winter. Obviously, we expect that there will soon be changes in public policy. Even before these challenges, US is already seeing a major wave of new infection coming with several states reporting intensive care united overloaded. 38, 39 Remdesivir is the first antiviral drug authorized for emergency use (EUA) by US FDA for the treatment of COVID-19. 40 A recent update on the effects of Pfizer mRNA 2 dose vaccination regime showed a reduction of hospital admission (i.e., their efficacy endpoint) from 95% to 87.9%, while the prevalence of Delta variant is increasing. 19 As the host immune response is polyclonal against different B-cell/T-cell epitopes on the RBD based vaccine, it was not surprising that the vaccinees are still protected, and although some epitopes might be impacted by amino acid substitutions, exposure to vaccines enhance the host immune system and prevent development of severe COVID-19. 43 Recently, there were updated report that the Pfizer vaccine is 64% efficacy against infection and preventing symptomatic cases but is 93% effective in preventing hospitalization/severe disease due to Delta variant. 44 As of August 2021, another set of data showed that Moderna dropped from 86% to 76% efficacy against infection and Pfizer has dropped to 42%, while Delta variant is evolving as the dominant strain. 45, 46 Johnson and Johnson (JNJ) vaccine demonstrated 73.1% efficacy in preventing severe disease/hospitalization/death but no sub-analysis was performed for its efficacy against the Delta variant. 47 Against the Beta variant however, the efficacy of JNJ vaccine dropped to 52%. 47 Pfizer and BioNTech released a statement in early July 2021 that their booster trial Nasal administered vaccines are also in development, and it is possible that this may enhance local immune response to better protect the upper airways, which is where the body is first exposed to the virus. 50 There are no approved inhalational vaccines yet, but in non-human primates, early humoral IgA immune responses has been shown to reduce viral shedding/transmission . 50 It is also important to emphasize that these variants will sustain the current pandemic, and there will certainly be more long-term implications on social/psychological/mental. The The genetic sequence, origin, and diagnosis of SARS-CoV-2 World Health Organization. WHO Coronavirus (COVID-19) Dashboard World health Organization Functional comparison of SARS-CoV-2 with closely related pangolin and bat coronaviruses Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update. Cureus Structural Evaluation of the Spike Glycoprotein Variants on SARS-CoV-2 Transmission and Immune Evasion Introduction to RNA Viruses World-wide Sequence Variant and Non-synonymous Amino Acid Substitution Signature in SARS-COV-2 Structural Proteins All the SARS-CoV-2 viruses in the world weigh as little as an apple and as much as a small toddler SARS-CoV-2 Variant Classifications and Definitions World Health Organization. COVID-19 Weekly Epidemiological Update World Health Organization SARS-CoV-2 reinfection caused by the P.1 lineage in Araraquara city, Sao Paulo State Ministry of Health and Family Welfare (IN). Delta and Delta Plus Variants: Frequently Asked Questions. New Delhi (IN). PIB Mumbai What is the Delta variant of coronavirus with K417 mutation? Reuters Lab Advisory: SARS-CoV-2 Variants AY.1 and AY.2 Now Aggregated with Delta Variant B.1.617.2. Atlanta (GA): CDC; 2021 July6 Delta variant spurring uptick in COVID-19 cases largely in unvaccinated How the coronavirus infects cells -and why Delta is so dangerous BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants Assessment of infectivity and the impact on neutralizing activity of immune sera of the COVID-19 variant SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity The SARS-CoV-2 spike L452R-E484Q Co-variant Nonsynonymous Substitutions in the Indian B.1.617.1 strain Showed Significant Reduction in the Neutralization Activity of Immune Sera Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation, Brazil. Emerg Infect Dis SARS-CoV-2 spike P681R mutation enhances and accelerates viral fusion Preliminary report on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike mutation T478K The 'Delta Plus' variant has spread to nearly 30 countries, but low case numbers are a sign it won't overtake Delta Yahoo news How the Delta variant achieves its ultrafast spread Delta waves in India and the U.K. have already receded. Could the same happen in the The Visual and Data Journalism Team. Covid vaccine: How many people in the UK have been vaccinated so far? GB): BBC news World Health Organization. COVID-19 Weekly Epidemiological Update CH); WHO What does the Delta variant have in store for the United States? We asked coronavirus experts Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings -Barnstable County The immune system and COVID-19: Friend or foe Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study These are the symptoms of the COVID-19 delta variant The Bellingham Herald Read: Internal CDC document on breakthrough infections The Washington Post Guidance For Fully Vaccinated People Emerging evidence shows Delta variant may cause mild COVID among vaccinated people Yahoo News Texas is running out of ICU beds as U.S. daily average of COVID cases tops 100,000 to mark highest level since February Final report confirms remdesivir benefits for COVID-19. Bethesda (MD): National Institute of Health Gilead's Veklury (Remdesivir) associated with a reduction in mortality rate in hospitalized patients with COVID-19 across three analyses of large retrospective realworld data sets CA): Gilead with-a-reduction-in-mortalityrate-in-hospitalized-patients-with-covid19-across-three-analyses-of-large-ret 42. National Institute of Health. Anti-SARS-CoV-2 Monoclonal Antibodies. Bethesda (MD): National Institute of Health; [date unknown Cellular and Humoral Immune Responses in Covid-19 and Immunotherapeutic Approaches. Immunotargets Ther Israel says Pfizer vaccine just 64% effective in real world as delta variant continues to spread rapidly New data suggests Pfizer and Moderna's vaccines may be less effective against Delta Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 Pfizer and BioNTech Provide Update on Booster Program in Light of the Delta-Variant Delta COVID variant now dominant strain worldwide, U.S. deaths surge -officials GB): Reuters Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines? European Centre for Disease Prevention and Control. SARS-CoV-2 variants of concern as of 5 The N501Y spike substitution enhances SARS-CoV-2 transmission The N501Y and K417N mutations in the spike protein of SARS-CoV-2 alter the interactions with both hACE2 and human derived antibody: A Free energy of perturbation study